Invention in the REGENERATIVE MEDICINE is what we do every day, benefits of patients is our final goal

Our Products

Home > Products

Cata #: Name of Product: Price:
HRP-2020 Recombinant Human CT89 N-terminal-11R Protein $300

Recombinant Human CT89 N-terminal-11R Protein

Product Name: Recombinant Human CT89 N-terminal-11R Protein
Catalog #:  HRP-2020
Manufacture:  LD Biopharma, Inc.

Human C-Jun-amino-terminal kinase-interacting protein 4 (SPAG9, also named as CT89) encodes 1321aa protein. The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. Isoform 5 may play a role in spermatozoa-egg-interaction. Normally, this gene expression is restricted in human testis tissue, but it also expressed in a wide variety of cancer tissues. As such, CT89 is a good candidate protein for anti-tumor vaccine development.

N-terminal domain of human CT89 cDNA (2 - 638aa, derived from BC146755) was constructed with codon optimization gene synthesis and expressed with a human Alpha Fetal protein at N-terminal and 11 arginine (11R tag) at C-terminal. This protein was expressed in E. coli as inclusion bodies. The final product was refolded using our unique “temperature shift inclusion body refolding” technology and chromatographically purified.

Gene Symbol:  CT89 (SPAG9: HSS; KIAA0516; MAPK8IP4; SYD1) 
Accession Number:  NP_001124000
Species:  Human
Package Size:  50 µg / Vial   
Composition: 0.5 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, Sucrose and DTT.
Storage: In Liquid. Keep at -80°C for long term storage. Product is stable at 4 °C for at least 30 days.
Key Reference: Ren B, et al., Cancer testis antigen SPAG9 is a promising marker for the diagnosis and treatment of lung cancer. Oncol. Rep. 35 (5), 2599-2605 (2016)
Wang X, et al., MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma. Biochem. Biophys. Res. Commun. 470 (3), 620-626 (2016)
Zhang,L., et al., SPAG9 promotes endometrial carcinoma cell invasion through regulation of genes related to the epithelial-mesenchymal transition. Eur. J. Gynaecol. Oncol. 37 (3), 312-319 (2016)
Salmaninejad A, et al. Cancer/Testis Antigens: Expression, regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Immunol Invest. Oct; 45(7): 619-640. (2016).
Nicole Brooks, et al. Comparative Immunogenicity of a Cytotoxic T cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides. Molecules. 20, 14033-14050. (2015)
Madiha Derouazi, et al. Novel cell penetration peptide based vaccine induces robust CD4+ and CD8+ T cell mediated antitumor immunity. Cancer Res; 75(15) August 1, 3020-3031 (2015)

1. May be used for in vitro CT89 mediated anti-tumor immunotherapy for T cell activation study with this fusion protein for intracellular delivery in MHC-II pathway.

2. As immunogen for specific antibody production.

Quality Control: Purity: > 80% by SDS-PAGE.
Download Datasheet